Literature DB >> 19321370

Novel variants of the human flavin-containing monooxygenase 3 (FMO3) gene associated with trimethylaminuria.

Meike S Motika1, Jun Zhang, Xueying Zheng, Kiersten Riedler, John R Cashman.   

Abstract

The disorder trimethylaminuria (TMAu) often manifests itself in a body odor for individuals affected. TMAu is due to decreased metabolism of dietary-derived trimethylamine (TMA). In a healthy individual, 95% or more of TMA is converted by the flavin-containing monooxygenase 3 (FMO3, EC 1.14.13.8) to non-odorous trimethylamine N-oxide (TMA N-oxide). Several single nucleotide polymorphisms (SNPs) of the FMO3 gene have been described and result in an enzyme with decreased or abolished functional activity for TMA N-oxygenation thus leading to TMAu. Herein, we report two novel mutations observed from phenotyping and genotyping two self-reporting individuals. Sequence analysis of the exon regions of the FMO3 gene of a young woman with severe TMAu revealed heterozygous mutations at positions 187 (V187A), 158 (E158K), 308 (E308G), and 305 (E305X). Familial genetic analysis showed that the E158K/V187A/E308G derived from the same allele from the mother, and the E305X was derived from the father. FMO3 variants V187A and V187A/E158K were characterized for oxygenation of several common FMO3 substrates (i.e., 5- and 8-DPT, mercaptoimidazole (MMI), TMA, and sulindac sulfide) and for its thermal stability. Our findings show that with the combination of V187A/E158K mutations in FMO3, the enzyme activity is severely affected and possibly contributes to the TMAu observed. In another study, genotyping analysis of a 17 year old female revealed a mutation that caused a frame shift after K415 and resulted in a protein variant with only 486 amino acid residues that was associated with severe TMAu.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19321370      PMCID: PMC2739593          DOI: 10.1016/j.ymgme.2009.02.006

Source DB:  PubMed          Journal:  Mol Genet Metab        ISSN: 1096-7192            Impact factor:   4.797


  42 in total

1.  Trimethylaminuria: susceptibility of heterozygotes.

Authors:  S C Mitchell
Journal:  Lancet       Date:  1999 Dec 18-25       Impact factor: 79.321

2.  Mechanism of action of a flavin-containing monooxygenase.

Authors:  Subramaniam Eswaramoorthy; Jeffrey B Bonanno; Stephen K Burley; Subramanyam Swaminathan
Journal:  Proc Natl Acad Sci U S A       Date:  2006-06-15       Impact factor: 11.205

3.  Exacerbation of symptoms of fish-odour syndrome during menstruation.

Authors:  A Q Zhang; S C Mitchell; R L Smith
Journal:  Lancet       Date:  1996 Dec 21-28       Impact factor: 79.321

4.  Population distribution of human flavin-containing monooxygenase form 3: gene polymorphisms.

Authors:  J R Cashman; J Zhang; J Leushner; A Braun
Journal:  Drug Metab Dispos       Date:  2001-12       Impact factor: 3.922

5.  Stereoselective sulfoxidation of sulindac sulfide by flavin-containing monooxygenases. Comparison of human liver and kidney microsomes and mammalian enzymes.

Authors:  M A Hamman; B D Haehner-Daniels; S A Wrighton; A E Rettie; S D Hall
Journal:  Biochem Pharmacol       Date:  2000-07-01       Impact factor: 5.858

6.  Alternative processing of the human FMO6 gene renders transcripts incapable of encoding a functional flavin-containing monooxygenase.

Authors:  Ronald N Hines; Kathleen A Hopp; Jose Franco; Kia Saeian; Frank P Begun
Journal:  Mol Pharmacol       Date:  2002-08       Impact factor: 4.436

7.  Revealing the moonlighting role of NADP in the structure of a flavin-containing monooxygenase.

Authors:  Andrea Alfieri; Enrico Malito; Roberto Orru; Marco W Fraaije; Andrea Mattevi
Journal:  Proc Natl Acad Sci U S A       Date:  2008-04-28       Impact factor: 11.205

8.  Two new polymorphisms of the FMO3 gene in Caucasian and African-American populations: comparative genetic and functional studies.

Authors:  Virginie Lattard; Jun Zhang; Quyen Tran; Bjarte Furnes; Daniel Schlenk; John R Cashman
Journal:  Drug Metab Dispos       Date:  2003-07       Impact factor: 3.922

9.  The reductive half-reaction of liver microsomal FAD-containing monooxygenase.

Authors:  N B Beaty; D P Ballou
Journal:  J Biol Chem       Date:  1981-05-10       Impact factor: 5.157

10.  Effects of the dietary supplements, activated charcoal and copper chlorophyllin, on urinary excretion of trimethylamine in Japanese trimethylaminuria patients.

Authors:  Hiroshi Yamazaki; Masaki Fujieda; Masahiro Togashi; Tetsuya Saito; George Preti; John R Cashman; Tetsuya Kamataki
Journal:  Life Sci       Date:  2004-04-16       Impact factor: 5.037

View more
  10 in total

1.  Clinical utility gene card for: trimethylaminuria.

Authors:  Elizabeth A Shephard; Eileen P Treacy; Ian R Phillips
Journal:  Eur J Hum Genet       Date:  2011-11-30       Impact factor: 4.246

2.  Characterization of human flavin-containing monooxygenase (FMO) 3 and FMO5 expressed as maltose-binding protein fusions.

Authors:  Robert R Reddy; Erik C Ralph; Meike S Motika; Jun Zhang; John R Cashman
Journal:  Drug Metab Dispos       Date:  2010-09-01       Impact factor: 3.922

3.  Trimethylaminuria: causes and diagnosis of a socially distressing condition.

Authors:  Richard J Mackay; Christopher J McEntyre; Caroline Henderson; Michael Lever; Peter M George
Journal:  Clin Biochem Rev       Date:  2011-02

4.  Clinical utility gene card for: Trimethylaminuria - update 2014.

Authors:  Elizabeth A Shephard; Eileen P Treacy; Ian R Phillips
Journal:  Eur J Hum Genet       Date:  2014-10-22       Impact factor: 4.246

5.  Analysis of six novel flavin-containing monooxygenase 3 (FMO3) gene variants found in a Japanese population suffering from trimethylaminuria.

Authors:  Makiko Shimizu; Yumi Origuchi; Marika Ikuma; Nanako Mitsuhashi; Hiroshi Yamazaki
Journal:  Mol Genet Metab Rep       Date:  2015-11-07

6.  Genetic analysis of impaired trimethylamine metabolism using whole exome sequencing.

Authors:  Yiran Guo; Liang-Dar Hwang; Jiankang Li; Jason Eades; Chung Wen Yu; Corrine Mansfield; Alexis Burdick-Will; Xiao Chang; Yulan Chen; Fujiko F Duke; Jianguo Zhang; Steven Fakharzadeh; Paul Fennessey; Brendan J Keating; Hui Jiang; Hakon Hakonarson; Danielle R Reed; George Preti
Journal:  BMC Med Genet       Date:  2017-02-15       Impact factor: 2.103

7.  Effects of FMO3 Polymorphisms on Pharmacokinetics of Sulindac in Chinese Healthy Male Volunteers.

Authors:  Yong-Jun Tang; Kai Hu; Wei-Hua Huang; Chong-Zhi Wang; Zhi Liu; Yao Chen; Dong-Sheng Ouyang; Zhi-Rong Tan; Hong-Hao Zhou; Chun-Su Yuan
Journal:  Biomed Res Int       Date:  2017-02-26       Impact factor: 3.411

8.  Plasma levels of trimethylamine-N-oxide can be increased with 'healthy' and 'unhealthy' diets and do not correlate with the extent of atherosclerosis but with plaque instability.

Authors:  Yen Chin Koay; Yung-Chih Chen; Jibran A Wali; Alison W S Luk; Mengbo Li; Hemavarni Doma; Rosa Reimark; Maria T K Zaldivia; Habteab T Habtom; Ashley E Franks; Gabrielle Fusco-Allison; Jean Yang; Andrew Holmes; Stephen J Simpson; Karlheinz Peter; John F O'Sullivan
Journal:  Cardiovasc Res       Date:  2021-01-21       Impact factor: 10.787

9.  Inactivation mechanism of N61S mutant of human FMO3 towards trimethylamine.

Authors:  Chongliang Gao; Gianluca Catucci; Silvia Castrignanò; Gianfranco Gilardi; Sheila J Sadeghi
Journal:  Sci Rep       Date:  2017-11-07       Impact factor: 4.379

Review 10.  Drug Discovery and Development of Novel Therapeutics for Inhibiting TMAO in Models of Atherosclerosis and Diabetes.

Authors:  Ian Steinke; Nila Ghanei; Manoj Govindarajulu; Sieun Yoo; Juming Zhong; Rajesh H Amin
Journal:  Front Physiol       Date:  2020-10-29       Impact factor: 4.566

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.